Literature DB >> 15037695

Essential tremor course and disability: A clinicopathologic study of 20 cases.

Alexander Rajput1, Christopher A Robinson, Ali H Rajput.   

Abstract

OBJECTIVE: To correlate autopsy findings with the clinical course and disability profile in clinically diagnosed longitudinally followed autopsied essential tremor (ET) patients.
METHODS: All ET patients followed by one neurologist between 1970 and 2001 who came to autopsy were included. Clinical features and disability were recorded prospectively. Autopsy studies were performed by a qualified neuropathologist.
RESULTS: Twenty cases (10 men and 10 women) had ET onset between childhood and age 68 (median 46.5 years). Six cases had additional features of Parkinson syndrome (PS), with presence of bradykinesia, rigidity, and rest tremor (RT). These included progressive supranuclear palsy (PSP; n = 2), drug-induced parkinsonism (n = 2), idiopathic Parkinson disease (PD; n = 1), and basal ganglia status cribrosus (n = 1). Of the remaining 14 ET cases, 6 had additional RT but no bradykinesia or rigidity. Ten of these 14 (71%) reported physical disability. Eleven of the 14 (79%) had only upper limb (UL) tremor at onset, and 8 of these 11 (73%) had subsequent cranial extension of tremor. Two patients clinically had mild cerebellar ataxia but no cerebellar histologic abnormality. There was no consistent brain pathology in the ET or ET + RT cases.
CONCLUSIONS: UL tremor was the most common onset, which often progressed to the cranial musculature. Functional disability and psychological distress were common in these patients. Functional disability was related to the UL tremor. Six of 20 (30%) had additional features of PS. Six of the remaining 14 (43%) had ET and RT; there was no identifiable pathology in these cases. The risk of PD in ET cases was comparable with that in the general population. PSP in two cases was incidental comorbidity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037695     DOI: 10.1212/01.wnl.0000115145.18830.1a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  53 in total

1.  Essential tremor and Parkinson's disease: lack of a link.

Authors:  Charles H Adler; Holly A Shill; Thomas G Beach
Journal:  Mov Disord       Date:  2011-01-31       Impact factor: 10.338

Review 2.  The emerging neuropathology of essential tremor.

Authors:  Elan D Louis; Jean Paul G Vonsattel
Journal:  Mov Disord       Date:  2008-01-30       Impact factor: 10.338

3.  Reduced Purkinje cell number in essential tremor: a postmortem study.

Authors:  Jordan E Axelrad; Elan D Louis; Lawrence S Honig; Ingrid Flores; G Webster Ross; Rajesh Pahwa; Kelly E Lyons; Phyllis L Faust; Jean Paul G Vonsattel
Journal:  Arch Neurol       Date:  2008-01

4.  Essential tremor: is it a neurodegenerative disease? No.

Authors:  Monica M Kurtis
Journal:  J Neural Transm (Vienna)       Date:  2012-08-17       Impact factor: 3.575

5.  Essential tremor is a neurodegenerative disease.

Authors:  Ubaldo Bonuccelli
Journal:  J Neural Transm (Vienna)       Date:  2012-08-23       Impact factor: 3.575

Review 6.  From neurons to neuron neighborhoods: the rewiring of the cerebellar cortex in essential tremor.

Authors:  Elan D Louis
Journal:  Cerebellum       Date:  2014-08       Impact factor: 3.847

Review 7.  An update on essential tremor.

Authors:  Rodger J Elble; Günther Deuschl
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

Review 8.  Essential tremor followed by progressive supranuclear palsy: postmortem reports of 11 patients.

Authors:  Elan D Louis; Rachel Babij; Karen Ma; Etty Cortés; Jean-Paul G Vonsattel
Journal:  J Neuropathol Exp Neurol       Date:  2013-01       Impact factor: 3.685

Review 9.  Linking Essential Tremor to the Cerebellum: Neurochemical Evidence.

Authors:  Juan Marin-Lahoz; Alexandre Gironell
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

10.  Essential tremor 10, 20, 30, 40: clinical snapshots of the disease by decade of duration.

Authors:  E D Louis; M Gerbin; M Galecki
Journal:  Eur J Neurol       Date:  2013-03-21       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.